Literature DB >> 18386459

L1 (CAM) (CD171) in ovarian serous neoplasms.

A Daponte1, E Kostopoulou, P Kollia, R Papamichali, P Vanakara, C Hadjichristodoulou, M Nakou, S Samara, G Koukoulis, I E Messinis.   

Abstract

PURPOSE OF THE INVESTIGATION: The evaluation of L1 (CAM) as a tumor progression marker and as a prognostic factor in serous ovarian tumors.
METHODS: L1 (CAM) protein expression was assessed by immunohistochemistry and Western blot in serous ovarian tumors [cystadenomas (n = 20), borderline tumors (n = 14) and carcinomas (n = 47)], and was correlated with stage,grade, progression-free survival time (PFS) and overall survival.
RESULTS: L1 (CAM) immunoreactivity correlated significantly with stage and grade. It increased from benign tumors to early carcinomas and to advanced stage carcinomas progressively and significantly. In Stage III G3 carcinoma patients, low L1 (CAM) expressing tumors exhibited better response to chemotherapy and were associated with statistically significantly longer PFS (p = 0.002).
CONCLUSION: L1 (CAM) expression represents a novel diagnostic marker in serous ovarian neoplasms that shows characteristics of tumor progression. L1 expression was associated with chemotherapy response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386459

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  11 in total

1.  Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.

Authors:  Mijung Kim; Lisa Rooper; Jia Xie; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

Review 2.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

3.  L1CAM in the Early Enteric and Urogenital System.

Authors:  Elisabeth Judith Pechriggl; Nicole Concin; Michael J Blumer; Mario Bitsche; Marit Zwierzina; Jozsef Dudas; Katarzyna Koziel; Peter Altevogt; Alain-Gustave Zeimet; Helga Fritsch
Journal:  J Histochem Cytochem       Date:  2016-11-12       Impact factor: 2.479

4.  Inside-out regulation of L1 conformation, integrin binding, proteolysis, and concomitant cell migration.

Authors:  Maxine M Chen; Chia-Yao Lee; Hyuma A Leland; Grace Y Lin; Anthony M Montgomery; Steve Silletti
Journal:  Mol Biol Cell       Date:  2010-03-24       Impact factor: 4.138

5.  Tyrosine and serine phosphorylation regulate the conformation and subsequent threonine phosphorylation of the L1 cytoplasmic domain.

Authors:  Maxine M Chen; Hyuma A Leland; Chia-Yao Lee; Steve Silletti
Journal:  Biochem Biophys Res Commun       Date:  2009-08-29       Impact factor: 3.575

6.  Modification of the L1-CAM carboxy-terminus in pancreatic adenocarcinoma cells.

Authors:  Maxine M Chen; Chia-Yao Lee; Hyuma A Leland; Steve Silletti
Journal:  Tumour Biol       Date:  2010-11-16

7.  Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.

Authors:  Samira Abdel Azim; Michaela Duggan-Peer; Susanne Sprung; Daniel Reimer; Heidi Fiegl; Afschin Soleiman; Christian Marth; Alain G Zeimet
Journal:  Oncotarget       Date:  2016-06-14

Review 8.  Prognostic significance of L1 cell adhesion molecule in cancer patients: A systematic review and meta-analysis.

Authors:  Teng Hua; Shuangge Liu; Xiaoyan Xin; Zhishan Jin; Qibin Liu; Shuqi Chi; Xiaoxiao Wang; Hongbo Wang
Journal:  Oncotarget       Date:  2016-12-20

9.  The sL1CAM in sera of patients with endometrial and ovarian cancers.

Authors:  Michał Wojciechowski; Ewa Głowacka; Miłosz Wilczyński; Anna Pękala-Wojciechowska; Andrzej Malinowski
Journal:  Arch Gynecol Obstet       Date:  2016-11-10       Impact factor: 2.344

10.  L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.

Authors:  Hao Hong; Christine E Brown; Julie R Ostberg; Saul J Priceman; Wen-Chung Chang; Lihong Weng; Paul Lin; Mark T Wakabayashi; Michael C Jensen; Stephen J Forman
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.